Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 42


Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, Wang J, Castle EP, Stanton ML, Cheville JC, Jonasch E, Brugarolas J, Parker AS.

Mod Pathol. 2015 Oct 30. doi: 10.1038/modpathol.2015.123. [Epub ahead of print]


PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, Bryce AH, Vogelzang NJ, Stanton ML, Castle EP, Ho TH.

Cancer Immunol Res. 2015 Aug 25. [Epub ahead of print]


Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J.

J Urol. 2015 Aug 20. pii: S0022-5347(15)04611-X. doi: 10.1016/j.juro.2015.07.113. [Epub ahead of print]


A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.

Ho TH, Nateras RN, Yan H, Park JG, Jensen S, Borges C, Lee JH, Champion MD, Tibes R, Bryce AH, Carballido EM, Todd MA, Joseph RW, Wong WW, Parker AS, Stanton ML, Castle EP.

PLoS One. 2015 Jul 16;10(7):e0132831. doi: 10.1371/journal.pone.0132831. eCollection 2015.


High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.

Ho TH, Park IY, Zhao H, Tong P, Champion MD, Yan H, Monzon FA, Hoang A, Tamboli P, Parker AS, Joseph RW, Qiao W, Dykema K, Tannir NM, Castle EP, Nunez-Nateras R, Teh BT, Wang J, Walker CL, Hung MC, Jonasch E.

Oncogene. 2015 Jun 15. doi: 10.1038/onc.2015.221. [Epub ahead of print]


Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.


Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature.

Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, Joseph RW.

Rare Tumors. 2015 Feb 25;7(1):5719. doi: 10.4081/rt.2015.5719. eCollection 2015 Feb 11.


Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

Swaika A, Hammond WA, Joseph RW.

Mol Immunol. 2015 Oct;67(2 Pt A):4-17. doi: 10.1016/j.molimm.2015.02.009. Epub 2015 Mar 5. Review.


Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences.

Grotz TE, Joseph RW, Pockaj BA, Foote RL, Otley CC, Bagaria SP, Weaver AL, Jakub JW.

Ann Surg Oncol. 2015 Nov;22(12):4060-6. doi: 10.1245/s10434-015-4421-7. Epub 2015 Feb 13.


Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Parasramka M, Cheville JC, Wu KJ, Frenkel E, Rakheja D, Stefanius K, Brugarolas J, Parker AS.

Urol Oncol. 2015 Jan;33(1):23.e9-14. doi: 10.1016/j.urolonc.2014.10.014. Epub 2014 Nov 24.


Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.

Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, Bagaria S, Jambusaria-Pahlajani A.

Cancer Immunol Res. 2015 Jan;3(1):18-22. doi: 10.1158/2326-6066.CIR-14-0134. Epub 2014 Oct 6.


c-MET expression in primary and liver metastases in uveal melanoma.

Gardner FP, Serie DJ, Salomao DR, Wu KJ, Markovic SN, Pulido JS, Joseph RW.

Melanoma Res. 2014 Dec;24(6):617-20. doi: 10.1097/CMR.0000000000000118.


Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis.

Eckel-Passow JE, Igel DA, Serie DJ, Joseph RW, Ho TH, Cheville JC, Parker AS.

Urol Oncol. 2015 Feb;33(2):68.e17-23. doi: 10.1016/j.urolonc.2014.07.019. Epub 2014 Aug 28.


Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A.

Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.


Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.

Swaika A, Crozier JA, Joseph RW.

Drug Des Devel Ther. 2014 Jun 16;8:775-87. doi: 10.2147/DDDT.S31143. eCollection 2014.


Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Joseph RW, Parasramka M, Eckel-Passow JE, Serie D, Wu K, Jiang L, Kalari K, Thompson RH, Huu Ho T, Castle EP, Cheville J, Kwon ED, Thompson EA, Parker A.

Cancer Immunol Res. 2013 Dec;1(6):378-85. doi: 10.1158/2326-6066.CIR-13-0042. Epub 2013 Aug 29.


Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass.

Starr JS, Attia S, Joseph RW, Menke D, Casler J, Smallridge RC.

J Clin Oncol. 2015 Jun 10;33(17):e74-6. doi: 10.1200/JCO.2013.49.3213. Epub 2014 Mar 24. No abstract available.


Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA.

Cancer Immunol Res. 2013 Dec;1(6):373-7. doi: 10.1158/2326-6066.CIR-13-0092.


ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma.

Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Cheville JC, Parker AS.

BMC Urol. 2014 Jan 31;14:14. doi: 10.1186/1471-2490-14-14.


Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.

Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC, Leibovich BC.

Eur Urol. 2014 Nov;66(5):929-35. doi: 10.1016/j.eururo.2013.12.017. Epub 2013 Dec 25.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk